<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li><a href="recomendaciones.html">2. Recommendations</a></li>
							<li class="active"><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div>
					  </div>
					</nav>
					</div>
				</div>

			</div>

		</div>
	</header>



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>Toxicities</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>


						</div>
					</div>
				</div>
			</div>
		</div>
	</section>




	<section class="franja">
	 <div class="overlay_franja">
		 <div class="container">
			 <div class="row">
				 <div class="col-md-12 col-sm-12 col-xs-12">
					 <div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
						 <h2>3<span class="negrita">.6</span> CUTANEOUS TOXICITY</h2>
						 <br/> <img src="images/piel.png" alt="" height="50px"/>

					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
 </section>




 <section class="texto">
	 <div class="container">
		 <div class="row">
			 <div class="parrafo wow zoomIn" data-wow-duration="0.5s">
				 <h2>Introduction</h2>
				 <br/>
				 <p>Skin toxicities are the most common immune-mediated toxicities. They have been described in 43-45% of patients being treated with Ipilimumab (anti-CTLA-4), presenting mainly in the form of rash and pruritus, followed by vitiligo.</p>
				 <br/>
				 <p><span class="decorado">&nbsp;The rash&nbsp;</span> is usually reticular, erythematous, oedematous and maculopapular, affecting generally the trunk and extremities.</p>
				 <br/>
				 <p><span class="decorado">&nbsp;Vitiligo&nbsp;</span> occurs in 10% of patients, being observed more frequently in patients treated with anti-PD-1 than with anti-TCLA-4, mainly affected by melanomas.</p>
				 <br/>
				 <p><span class="decorado">&nbsp;Pruritus&nbsp;</span> usually occurs in 6-20% of patients treated with anti-PD-1 and up to 35% with anti-CTLA-4, mostly in patients with melanoma.</p>
				 <br/>
				 <p>Severe presentation patterns such as Stevens-Johnson syndrome and toxic epidermal necrolysis usually appear very isolated and, mainly, in cases of combined treatments with anti-PD-1 / PDL-1 and anti-CTLA-4 with an incidence of 4.8%.</p>
				 <br/>
				 <p>Currently, there is no premedication indicated as prophylaxis for immune-mediated cutaneous toxicities.</p>
				 <br/>
				 <p><span class="negrita">Health education: It is important that the patient has good skin hygiene and moisturisation, as well as correct sun protection against UV rays; correct health education is considered to be fundamental.</span></p>
			 </div>
		 </div>
	 </div>
 </section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">

							<img src="images/diagnostico.png" alt="" height="40px"/> <br/><br/>
							<h2>Diagnosis</h2>
							<br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Pruritus, mainly in the trunk and extremities.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Erythematous and maculopapular or acneiform or psoriasis type rash. In extreme cases, bullous type rash and with displacement/removal of the dermis layer.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Peeling and skin exfoliation.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Vitiligo with skin pigmentation. Discolouration of the skin.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Asthenia, fever, generalised weakness and symptoms of dehydration and infection in extreme cases.</p>
							<br/> <br/> <br/> <br/>
							<h2>Differential diagnosis</h2>
							<br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;A&nbsp;&nbsp;</span> Allergic/hypersensitivity reaction</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;B&nbsp;&nbsp;</span> Pharmacological cause (other drugs)</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;C&nbsp;&nbsp;</span> Cause of infection (bacteria, fungal, etc.)</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;D&nbsp;&nbsp;</span> Photosensitivity</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;E&nbsp;&nbsp;</span> Psoriasis</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;F&nbsp;&nbsp;</span> Dermatitis</p>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<h2>Therapeutic management</h2>
				<br/>
				<p>Monitor the signs and symptoms of dermatitis (rash and pruritus). The management of toxicities depends on the severity of the extension based on the Body Surface Area (BSA). Assessment by a dermatologist is recommended. If the patient has a bullous rash, the drug must be stopped immediately.</p>
				<br/>


				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 1:&nbsp;</span> <span class="turquesa">Rash/pruritus localised in &lt;10% of BSA</span>.</p>
				<p>Does not require discontinuation of the drug. Symptomatic treatment, including <span class="negrita">:</span></p>
				<br/>
				<p><span class="negrita">•</span> Oral antipruritic agents: antihistamines such as Diphenhydramine or Hydroxyzine, and topical: based on cold compresses, compresses soaked with oat milk.</p>
				<br/>
				<p><span class="negrita">•</span> Topical treatment with urea-based creams.</p>
				<br/>
				<p>If it does not improve, treat as <span class="turquesa">GRADE 2</span>.</p>
				</div>


				<br/>

				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 2:&nbsp;</span> <span class="turquesa">Moderate rash/pruritus affecting 10-30% of BSA</span>.</p>
				<br/>
				<p>Assessment by a dermatologist.</p>
				<br/>
				<p>Symptomatic treatment, including <span class="negrita">:</span></p>
				<br/>
				<p><span class="negrita">•</span> Oral antipruritic agents: antihistamines such as Diphenhydramine or Hydroxyzine, and topical: based on cold compresses, compresses soaked with oat milk.</p>
				<br/>
				<p><span class="negrita">•</span> Topical treatment with urea-based creams and betamethasone 0.1% (medium potency corticosteroid cream).</p>
				<br/>
				<p>If the symptoms do not improve within 3-5 days or worsen, start Prednisolone at 0.5-1mg/kg orally, reassessing and reducing the dose over a period of 1-2 weeks. Treatment should be delayed until there is improvement to <span class="turquesa">GRADE 1</span> or less, and with daily doses of oral prednisolone less than 10mg.</p>
				<p>If the rash persists or recurs at <span class="turquesa">GRADE 2</span>, treatment should be stopped and a skin biopsy should be considered.</p>
				</div>

				<br/>

				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 3/4:&nbsp;</span> <span class="turquesa">Severe rash/pruritus affecting &gt;30% of BSA</span>.</p>
				<br/>
				<p>Stop the treatment until resolution of the clinical picture to <span class="turquesa">GRADE 1</span> or less. If, despite the treatment, there has been no clinical improvement to <span class="turquesa">GRADE 1</span> or less within 30 days, the treatment will be permanently discontinued. In case of <span class="turquesa">GRADE 4</span>, permanent discontinuation of treatment.</p>
				<br/>
				<p>Assessment by a dermatologist for taking the biopsy.</p>
				<br/>
				<p>Consider hospital admission and monitor the extension of the rash.</p>
				<br/>
				<p>Symptomatic treatment, such as in <span class="turquesa">in GRADE 2</span>.</p>
				<br/>
				<p>Start methylprednisolone 1-2mg/kg/day intravenously (or equivalent), then reduce doses at ≥ 28 days, as the patient clinically improves. Consider prophylactic antibiotics and antifungal agents for opportunistic bacteria.</p>
				<br/>
				<p>In the event of Stevens–Johnson syndrome and toxic epidermal necrolysis, immediate hospital admission is required as well as multidisciplinary assessment by Dermatology and the Intensive Care Unit. These patients require intravenous fluid therapy with oral and electrolyte support, antibiotic prophylaxis and permanent discontinuation of treatment.</p>
				</div>

				<br/>


				<div class="marco wow fadeIn">
				<p><span class="decorado">&nbsp;GRADE 5:&nbsp;</span> <span class="turquesa">Death</span>.</p>
				</div>
				<br/>



			</div>
		</div>
	</div>
	</section>

	<section class="counterUp">
		<div class="counter_overlay">
			<div class="container">
				<div class="row">
					<div class="main_counter_content text-center">
						<div class="col-md-12 col-sm-12 col-xs-12">


							<h2>CLINICAL CASE</h2>
							<br/> <img src="images/pacienteICON.png" alt="" height="40px"/> <br/> <br/> <br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> 48-year-old patient with a history of: smoking habits (20 packs/year), hypertension without medical treatment and dyslipidaemia without medical treatment.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Diagnosis with a cT3N2M0 squamous cell carcinoma of the left side of the tongue treated with surgery using a left hemimandibulectomy and bilateral lymph node dissection. Due to high post-surgical risk criteria (extracapsular expansion in left level II lymph node), adjuvant treatment with chemo-radiotherapy was completed using cisplatin 100mg/m2 tri-weekly administration regimen (DT 60Gy). Subsequent controls followed. Non-resectable local and regional progression and not re-irradiable after 5 months of adjuvant treatment. Therefore, Nivolumab was started at a dose of 3mg/kg every 2 weeks (in a clinical trial). The best response is a partial response of the disease.</p>
							<br/><br/> <img src="images/medicinas.png" alt="" height="40px"/> <br/>
							<p><span class="negrita">3 months after the start of Nivolumab, the patient presents:</span></p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Haemodynamic stability, afebrile.</p>
							<br/>
							<p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Pruritus with maculopapular rash in upper extremities (BSA &lt; 10%)</p>
							<br/><br/>



							<div class="marcoOSCURO wow fadeIn">

							<form>
							<br/> <br/> <br/>
							<h2>What grade of rash would you assign to this patient? How would you manage it?</h2>
							<br/> <br/> <br/> <br/>
							<label class="container">It was a GRADE 1 rash (located in upper extremities in &lt;10% BSA), so it did not require drug discontinuation. Symptomatic treatment included: Oral antipruritic agents (antihistamines such as Diphenhydramine or Hydroxyzine), and topical agents (based on cold compresses, compresses soaked with oat milk) and treatment with urea-based creams.
								<input type="radio" name="pregunta1" id="p1">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">In spite of treatment, the patient did not feel better and was treated as GRADE 2. The patient was assessed by a dermatologist and treatment with Nivolumab was stopped.
								<input type="radio" name="pregunta1" id="p2">
								<span class="checkmark"></span>
							</label>
							<br/>
							<label class="container">After the initial treatment, 0.1% of betamethasone cream (average potency corticosteroid cream) was added, with clinical improvement after 3 days. It was therefore not necessary to initiate oral corticosteroid therapy. Once the episode was resolved, the patient restarted Nivolumab.
								<input type="radio" name="pregunta1" id="p3">
								<span class="checkmark"></span>
							</label>
							</form>

							<div class="pregunta wow fadeIn" data-wow-duration="1s">
								<a href="#"><img onclick="resultado();return false;" src="images/profesora.png" alt="" height="90px"/></a>
							</div>


								<div id="flotante" style="display:none;">
									<br/><br/>
									<h2>Correct! It is a GRADE 1 rash</h2>

								</div>
								<div id="flotanteIncorrecto" style="display:none;">
									<br/><br/>
									<h2>This is not correct. Try again :)</h2>

								</div>


							</div>



							<br/>

							<div class="contorno wow fadeIn">
							<h2>REMEMBER <span class="negrita">:</span></h2>
							<br/>
							<p><span class="negrita">•</span> It is important that the patient has good skin hygiene and moisturisation, as well as correct sun protection against UV rays; correct health education is considered to be fundamental.</span></p>
							<p><span class="negrita">•</span> To be able to evaluate skin toxicity, it is vital to know the corresponding percentages of body surface area (BSA).</p>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section>
	<section class="texto">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<div class="contenedor">
						<img src="images/toxcutanea01.png" alt="" class=""/>
					<p class="piefoto">Percentages of the body regions in adults. Wallace rule of nine</p>
  					<div class="sobreponer">
  					<img src="images/toxcutanea02.png" alt="" class=""/>
  					</div>
					</div>
			  </div>
			</div>
	</section>


	<section>
	 <div class="container">
		 <div class="row">

			 <div class="wedo_content_area">

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad01.html"><h4 class="gris">3.1 GASTROINTESTINAL TOX.</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad02.html"><h4 class="gris">3.2 PULMONARY TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad03.html"><h4 class="gris">3.3 RENAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad04.html"><h4 class="gris">3.4 LIVER TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad05.html"><h4 class="gris">3.5 ENDOCRINE TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contornoActivo wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad06.html"><h4 class="gris">3.6 CUTANEOUS TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad07.html"><h4>3<span class="turquesa">.7</span> NEUROLOGICAL TOXICITY</h4></a>
						 </div>
					 </div>
				 </div>

				 <div class="col-md-6 col-sm-6 col-xs-12">
					 <div class="contorno wow fadeIn" data-wow-duration="1s">
						 <div class="single_right_text">
							 <a href="toxicidad08.html"><h4>3<span class="turquesa">.8</span> OTHER TOXICITIES</h4></a>
						 </div>
					 </div>
				 </div>
			 </div>
		 </div>
	 </div>
	</section>


	<footer id="footer" class="footer">
		<div class="container">
			<div class="row">
				<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
					<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
				</div>
			</div>
		</div>
	</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>

	<script type="text/javascript" src="js/test.js"></script>




	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
